News
Public · Published
Goldman Sachs maintains Amgen at Buy, raises price target to $536 from $481
Goldman Sachs kept its Buy rating on Amgen and raised its price target to $536 from $481, an 11.4% increase. The new target implies 16.2% upside from Amgen's Nov. 3 closing price of $461.26.
Published:
Updated:
What happened
Goldman Sachs kept its Buy rating on Amgen and raised its price target to $536 from $481, an 11.4% increase. The new target implies 16.2% upside from Amgen’s Nov. 3 closing price of $461.26.
Confirmed
Global impact / market context
A higher target signals that Goldman Sachs sees more potential value in Amgen shares, which could influence investor expectations and positioning. If investors respond by buying shares, that could support the stock price, though the article reports no market reaction or change to the company’s business outlook.
Analyst inference
The five other recent analyst targets listed range from $398 to $470, below Goldman Sachs’ new $536 target. This shows a notable difference in published views, but analyst targets are estimates rather than guarantees and do not establish how Amgen’s sales, costs, or cash available will change.
Confirmed
What to watch
- Check whether later analyst updates move their targets closer to Goldman Sachs’ $536 view or maintain the lower range shown in the recent notes. Analyst inference
- Watch for company updates on sales, costs, or business outlook that could support or challenge the expectations behind analysts’ share-price estimates. Analyst inference
- Compare Amgen’s share price with the cited $461.26 Nov. 3 close and the $536 target; the article provides no subsequent trading data. Confirmed
Evidence
- Original source link unavailable